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ABSTRACT To avoid an antibiotic resistance crisis, we need to develop antibiotics
at a pace that matches the rate of evolution of resistance. However, the complex
functions performed by antibiotics—combining, e.g., penetration of membranes,
counteraction of resistance mechanisms, and interaction with molecular targets—
have proven hard to achieve with current methods for drug development, including
target-based screening and rational design. Here, we argue that we can meet the
evolution of resistance in the clinic with evolution of antibiotics in the laboratory.
On the basis of the results of experimental evolution studies of microbes in general
and antibiotic production in Actinobacteria in particular, we propose methodology
for evolving antibiotics to circumvent mechanisms of resistance. This exploits the
ability of evolution to find solutions to complex problems without a need for design.
We review evolutionary theory critical to this approach and argue that it is feasible
and has important advantages over current methods for antibiotic discovery.
KEYWORDS actinomycetes, antibiotic, evolution, experimental evolution, natural
antimicrobial products
The evolution of antibiotic resistance is a major threat to human health, and key tomeeting this challenge is the development of novel drugs (1). Despite early
successes during the “golden era” (2) of antibiotic discovery, however, drug develop-
ment is currently struggling to replenish the antibiotic arsenal at a sufficient rate to
maintain adequate treatment options. Natural product discovery programs that formed
the basis of the “golden era” were cancelled due to diminishing returns and problems
with dereplication, yet the programs that succeeded them, including high-throughput
target-based screening of synthetic compound libraries and rational drug design, have
yielded little (2). The shortcomings of these latter approaches have, in turn, resulted in
renewed interest in natural products and novel methods for their discovery (3–6).
However, while the modernized search for natural product antibiotics does have
potential (6), all methods for natural product discovery have a fundamental limitation
built into them: they are confined to compounds that have already evolved. We argue
that this limitation can be removed. That is, rather than merely discovering natural
product antibiotics, we can take control of the process that gives rise to them; we can
bring antibiotic evolution into the laboratory, and control it, to evolve the compounds
that we need. Though not an established method for drug development, experimental
evolution is a routine tool in evolutionary biology, and it has been successfully applied
to antibiotic production by Actinobacteria (7), the source of the majority of antibiotic
classes in clinical use.
In brief, we propose the following: when the utility of natural product antibiotics is
threatened by resistance, we can experimentally evolve organisms that produce these
compounds to circumvent the resistance mechanisms. This evolution may modify the
compounds to counteract how resistance is achieved (e.g., decrease the sensitivity of
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-lactams to degradation by -lactamases) or upregulate previously silent pathways to
produce novel antibiotics (7) or antiresistance molecules (e.g., -lactamase inhibitors).
An overview of the approach is given in Fig. 1.
WHY EVOLVE ANTIBIOTICS?
The starting point for the argument is a simple observation: it is evolution that has
the track record in antibiotic development. Despite extensive efforts with synthetic
chemistry approaches, most antibiotics in the clinic either are natural products or are
derived from such products (3), that is, they are ultimately the result of evolution. It is
thus unquestionable that evolution is apt to produce antibiotics. The question is “Can
adequate evolution be achieved in the laboratory on a reasonable timescale? Next, we
argue that it can.
Experimental evolution of antibiotics is feasible. First, natural product antibiotics
may be particularly well suited to evolutionary discovery and modification. The poten-
tial for discovery of novel compounds is indicated by the fact that Actinobacteria—the
antibiotic-producing bacteria that formed the basis of the “golden era” (2)—carry
genes that encode many cryptic pathways (2, 8) that experimental evolution may turn
on (7). There is also potential for modification of existing compounds. Consider the
cephalosporins, a key class of antibacterial drugs. These drugs consist of a core chemical
scaffold decorated with side chains, where the latter often modulate pharmacological
properties. Most notably, the R1 side chain affects the susceptibility of the compounds to
degradation by -lactamases, as well as their affinity for penicillin binding proteins (9). This
has formed a basis for semisynthetic chemistry to improve these drugs (9) and can provide
scope for evolutionary adaptation. A similar pattern with variations on a common core is
seen in the aminoglycosides, where it has likely facilitated evolution (10). Being synthesized
and decorated by multipart pathways with many enzymatic steps, natural product antibi-
otics can evolve by mutation, acquisition, or even loss of enzymes that determine their final
structure. In addition, evolution can interconnect different pathways to produce novel
compounds by combinatorial biosynthesis, as was recently reported for naturally evolved
systems (11, 12). It is plausible that the genes and gene clusters that encode components
of biosynthetic pathways are conducive to evolution, because their modular organization
facilitates rearrangement and other modification of genetic material (10). These routes to
compound improvement are a mere illustration of expected evolutionary potential, how-
ever; a key strength of the evolutionary process is precisely its ability to produce unantic-
ipated results by probing chemical space independently of prior knowledge and the toolkit
of synthetic chemistry.
Second, in a landmark study, Charusanti et al. used 4 months of experimental
evolution of Streptomyces clavuligerus in coculture with methicillin-resistant Staphylo-
coccus aureus to turn on a previously silent pathway for an antibiotic that inhibited the
growth of the target pathogen (7). This shows that adequate selection can be imposed
in the laboratory setting, that the producer organism can respond to such selection on
a practically useful timescale, and that upregulation of a silent biosynthetic pathway is
within the scope of experimental evolution. These results hold great promise, because
Clinic
Laboratory
Pathogens evolve
resistance
Producers evolve
around resistance
FIG 1 Proposed roles of evolution in the arms race between pathogens and drug development. An
evolutionary arms race between pathogens and drug development is illustrated. In clinical use, the
antibiotic is held constant, whereas pathogens respond by evolving resistance. Experimental evolution
of antibiotic-producing organisms is then used to modify the antibiotic or discover other compounds,
using resistant bacteria to impose selection. The novel or modified drug succeeds or complements the
original drug in clinical use.
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the development and optimization of methods to switch on silent pathways would
provide access to a vast untapped source of novel antibiotics (13). Beyond this
empirically known potential, we propose that experimental evolution can also mutate
and recombine biosynthetic gene clusters to modify compounds to perform their
functions better or upregulate several compounds that work in concert (e.g., antibiotics
and antiresistance compounds).
Experimental evolution has advantages over target-based screening and ra-
tional design. Natural evolution has been very successful in developing antibiotic
compounds. The discoveries during the “golden era” are a result of natural evolution,
and current trends toward revival of natural product discovery (see above) take it for
granted (and for good reason—the genus Streptomyces alone is estimated to be able
to produce more than 100,000 antimicrobial compounds [14], only a minute fraction of
which are in clinical use). We argue that there is reason to believe that the evolution of
producer organisms has an edge over current approaches to antibiotic development.
The function that an antibiotic has to perform—to kill or inhibit the target bacte-
rium—may seem simple, but in fact, it is complex and consists of several components.
These include the penetration of membranes, circumvention of resistance mechanisms,
and binding to target molecules, as relevant. As a consequence, useful molecules are
hard to identify by high-throughput screens for individual component functions or to
rationally design (2, 4). In addition, nonpeptide antibiotics are difficult targets for
so-called directed-evolution approaches, which are currently best developed for pep-
tides and proteins (15).
Experimental evolution, by contrast, like its natural counterpart, applies selection on the
producer organism as a whole and can thereby modify not only a single protein, gene, or
pathway but an entire metabolic system. It is therefore better suited for small-molecule
development than is the directed-evolution methodology. Moreover, and more impor-
tantly, by applying selection for a complex function on a rich metabolic system, experi-
mental evolution takes advantage of a key aspect of adaptive evolution: selection for a
complex function (e.g., target killing) entails selection for all its necessary component
functions (e.g., membrane penetration and resistance circumvention, as relevant). This
ability of evolution to subsume the optimization of individual mechanisms under a higher-
level function makes it possible to define the goal of the evolutionary process and apply
selection for attaining it, without explicitly addressing the chemical properties required. In
the case considered here, this goal is the killing of a resistant target bacterium, ideally under
physiologically realistic conditions. In Box 2 (point 10 in particular), we discuss problems
that may arise when translating this principle into practice.
HOW TO EVOLVE ANTIBIOTICS
The centerpiece of the approach is to evolve antibiotic-producing organisms around
resistance mechanisms by applying the appropriate selection pressure in the labora-
tory. The principal method is experimental evolution by serial passage in coculture,
where the antibiotic producer is subjected to antagonistic interaction (for example,
competition over nutrients) with a target organism that is resistant to its antibiotic, as
detailed in Box 1 and represented in Fig. 2.
In general, experimental evolution by serial passage is designed to allow adapta-
tions to evolve gradually, through a sequence of genetic changes, over many passages
and bacterial generations, and thereby create novel genotypes that are substantially
different from the genotype of the ancestral organism with which the procedure was
started. In the specific application we propose, the idea is to use the target organism
to impose selection pressure on the producer to evolve counteradaptations to the
target’s resistance.
We advocate antagonistic interactions with resistant organisms to impose selection
on the producer, rather than manually selecting colonies based on their killing zones
(a strategy with which it can in principle be combined). The reason is that antagonistic
interactions can select on individual cells or small cell clusters. This increases the
number of units of selection, a key parameter in experimental evolution. It also makes
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it possible to run the experiment in smaller volumes that are more conducive to
high-throughput methodologies. We anticipate that a 96-well format will yield pro-
ducer population sizes on the order of 106 cells. Because the efficacy of natural
selection depends on the product of effective population size and the magnitude of
selection coefficients (16), this will enable selection of even weakly beneficial alleles.
Evolution requires the presence of genetic variation, and mutation rates in producers
may be increased by the use of mutator strains or mutagens (see Box 2).
Experimental evolution of microorganisms is well established (17), and much of the
groundwork for what we advocate here has, consequently, been done. In the following,
we discuss evolutionary theory of key importance to its application to antibiotic
development. We keep the main text conceptual. In Box 1, we illustrate the experi-
mental evolution procedure with a protocol skeleton, and in Box 2, we address
potential problems.
Choosing producer and target organisms. The natural choice of producer organ-
ism are bacteria that are known to have a high potential for natural product biosyn-
thesis. Most notable in this regard are the Actinobacteria. These bacteria were the
mainstay of the “golden era” (2). They are a focus of recent efforts to revive natural
product discovery (8), and they have been successfully used for experimental evolution
of antibiotic production through competition with resistant target bacteria (7). In
addition, even well-studied Actinobacteria have cryptic pathways (2, 8) that experimen-
tal evolution can activate (7). This variety of pathways is also key to the evolutionary
modification of antibiotics; it provides scope for mutations that regulate, modify, or
hybridize different pathways to catalyze the reactions needed to improve the original
compound. If the genomes of single strains should not suffice to supply the necessary
genetic material and diversity for selection to act upon, the observation that biosyn-
thetic gene clusters are well adapted for horizontal transfer (18) suggests that the
genetic substrate can be extended to ensembles of strains or species. This could, in
principle, be achieved by artificial introduction of gene clusters into producer strains or
by coculture of genetically diverse producer bacteria.
While a genome (or population of genomes) possessing a rich set of biosynthetic
gene clusters provides evolutionary substrates for the evolution of pathways to new
compounds, this process may be constrained by the need for producer bacteria to
survive any new antibiotics that are produced. If, for example, the mechanism by which
the producer bacterium resists its compound is similar to the resistance mechanism of
the target bacterium, evolutionary changes that circumvent target resistance may be
suicidal for the producer. Adaptive evolution of the antibiotic due to selection for target
killing may then require simultaneous evolution of resistance in the producer. This
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FIG 2 Experimental evolution procedure. Two growth cycles of a serial passage are represented. The
producer (colored) competes with the target (black) in a structured medium. A mutant producer (purple)
has a competitive advantage due to an improved compound. An additional mutation (red) further
improves the compound, etc. As a result, the killing efficiency increases, and the target density decreases
over passages. The target’s density and degree of resistance can be adjusted to compensate.
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requirement is double edged: it limits the rate at which successful mutants arise,
because complementary mutations are needed in two systems, but once such mutants
are present, it also increases the efficiency of selection, since the mutant would kill not
only target bacteria but other producers as well. The problem may be avoided by
choosing producer and target bacteria with different mechanisms of resistance, so that
counteraction of target resistance is unlikely to interfere with producer resistance.
This issue also highlights that the optimal choice of producer organism depends on
the intended evolutionary outcome. If the goal is to discover compounds that have
already evolved in nature by turning on preexisting, but silent, pathways, a relatively
uncharacterized strain with a largely unexplored biosynthetic capacity seems best. If, on
the other hand, one aims to modify an antibiotic to avoid a resistance mechanism,
knowledge of the resistance mechanisms of both the target and producer is advanta-
geous, and a better-characterized producer strain may be preferable.
In addition to the Actinobacteria, on which we focus, Gamma- and Deltaproteobac-
teria may also be used as producers. For example, antibiotic-producing predatory
myxobacteria could be evolved to feed on resistant prey. (See references 19 and 20 for
reviews of antibiotics and other natural products in myxobacteria.)
The function of the target organism is to impose selection on the producer to kill it.
It should therefore interact antagonistically with the producer. The interaction may be
competition over a limiting resource or predation, where the producer organism gains
access to nutrients by lysing target cells. The results of Charusanti et al. (7), discussed
above, show that a resistant human pathogen can be used, but it is also possible to
express the resistance mechanism of interest in a vehicle organism. There are pros and
cons to both alternatives. The use of resistant human pathogens promotes medical
relevance, especially for evolutionary responses that do not directly interfere with the
resistance mechanism, but result in the killing of the target some other way, whereas
the cloning of resistance genes allows one to choose a vehicle organism that fits the
precise protocol to be used in the experimental evolution process. Pertaining to the
latter aspect are the ability to interact with the producer and to be easily separable
from it in serial transfers, so as to avoid evolution of the target.
Antibiotics are public goods. Adaptive evolution requires that the benefit con-
ferred by a mutation be enjoyed by individuals that carry that mutation rather than
individuals that do not. In many cases, this is not problematic. If, for example, a
population of bacteria is exposed to an antibiotic, and in one of the cells, a mutation
arises that decreases its susceptibility to the antibiotic, that cell will enjoy a benefit. If,
on the other hand, bacteria produce an antibiotic that kills competitors, and one
producer cell has a mutation that improves the potency of the antibiotic and thereby
reduces competition, selection does not necessarily favor that cell. The reason is that
the antibiotic is secreted into the environment, where it spreads by diffusion and mass
flow, to the benefit of all cells in the vicinity, regardless of whether they carry the
mutation or not. That is, antibiotics are not private, but public, goods.
In order to evolve antibiotics and similar compounds, it is therefore necessary to
devise a way to link the benefit associated with an improved version of a compound (or
the production of a novel compound) to cells that carry the underlying genotype.
Fortunately, the evolution of public goods has been extensively studied, and several
routes have been found (21–26). Here, we focus on the one we think is most practically
useful: spatial structure.
The key to spatial structure is the restriction of movement of cells and the molecules
that they produce. Since cells reproduce by division, population growth in structured
environments gives rise to clusters of cells that belong to the same clone. Due to their
clonality, the cells within a cluster tend to have, or lack, the same mutations, and
benefits conferred by such mutations will be preferentially enjoyed by cells that carry
those mutations, simply because cells with the same genotype are closer to each other
and to their products than are cells of different clones. In more general terms, the
variation in the compounds produced, and the underlying genotypes should be
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spatially structured. The degree of structure that is achieved depends on several factors,
including the medium used and the producer’s mode of growth. For example, the
filamentous growth of Actinobacteria may tend to mix genotypes to some extent. For
in vitro experimental evolution purposes, structure can be imposed by the addition of
a matrix material to the growth medium.
SUMMARY AND CONCLUSIONS
On the basis of the power of evolution to optimize molecular mechanisms, the
successes of experimental evolution of microorganisms, and the fact that experimental
evolution of antibiotic production in Actinobacteria has been achieved (7), we have here
advocated experimental evolution of antibiotics as a platform for drug development.
We have discussed evolutionary theory of critical importance, described a concrete
procedure (Box 1), and addressed potential problems (Box 2).
Clearly, we have only outlined a first sketch of the approach, and much work
remains. This is especially so on the empirical side, and it is to promote such work that
we have written this paper. If an empirical foundation is established, however, relevant
theory should also be developed further. Tasks that would benefit from theoretical
work include the optimization of selection regimes to overcome whole suites of
different resistance mechanisms with a single compound, as well as attaining a
desirable antimicrobial spectrum. Moving beyond antibiotics, Actinobacteria also pro-
duce other medically important molecules, most notably, cytostatics used in the
treatment of cancer. The application of experimental evolution to this context seems
particularly challenging, as the high degree of similarity between cancer cells and
healthy bystanders decreases the chances that a compound that is toxic to the former
is not also toxic to the latter. The chances may by increased with a more complex
evolution protocol that combines selection for toxicity to malignant cells and nontox-
icity to healthy cells.
In conclusion, we have argued that evolution—the process that gives rise to both
antibiotics and the resistance to them—can be leveraged to address the resistance
problem currently experienced in health care systems around the world. Specifically, we
make the case for experimental evolution in the laboratory to take control of the arms race
between pathogens and drug development, in which pathogens currently reign alone.
BOX 1―SKELETON PROTOCOL
Here, we sketch a protocol to provide a concrete illustration of the approach. The
procedure is represented in Fig. 2.
Material
The key materials are as follows:
1. An antibiotic-producing microorganism that is culturable and has a genome
that can give rise to relevant genetic and phenotypic variation (e.g., an
actinobacterium, whose genome contains a large variety of biosynthetic gene
clusters).
2. A target microorganism that has a relevant resistance mechanism and can
interact antagonistically with the producer. For the procedure we sketch
below, the target organism should be fluorescently labeled, and it should be
heat killed at a lower temperature than the producer (either naturally or by
genetic manipulation).
3. A medium that is conducive to the antagonistic interactions between the
producer and target organisms and provides adequate resistance to diffusion
of cells and compounds to allow evolution of public goods (e.g., antibiotics).
For the procedure we sketch below, the matrix material that provides the
diffusion resistance should liquefy at a temperature that is lower than the heat
killing temperature of the producer organism and solidify below the killing
temperature of the target.
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Serial passage
1. The producer organism is preevolved without the target organism or with a
sensitive target. This allows the producer to adapt to the medium, possible
mutagen, passage procedure, etc. It should therefore be performed exactly as
in points 2 and 3, only with the exclusion of the target or its resistance
mechanism.
2. The producer and target bacteria are cocultured in the medium. Either both
bacteria are added at the same time, or one is allowed to establish before the
other is added. In each growth cycle, fluorescence is measured to assess the
extent to which the target bacterium is killed or inhibited in each replicate.
3. The culture is heated to liquefy the medium and kill the target bacterium (but
not the producer), and agitated to break up cell clusters and mix the producer
population. An aliquot of the culture, containing live producer or spores, is
transferred to fresh medium, and mixed with fresh target bacteria. This
initiates a new cycle at point 2.
4. When fluorescence readings indicate increased target killing, relevant samples
are analyzed. For example, the MIDs (maximum inhibitory dilutions) or ED50s
(50% effective dilutions; the dilutions that prevent 50% of growth or kill 50%
of bacteria) of supernatants from evolved and nonevolved producers may be
determined for the resistant target and a sensitive control strain, to distinguish
improved potency of the product or product mixture from increased
production.
Comments
The use of spatial structure creates a spatial association between an improved or
novel compound and producer cells that share the underlying genotype. The
transfer procedure with breaking of bacterial clusters and mixing of cells results in
global scale competition among producers within replicates. Together, these two
aspects promote the evolution of public goods (21), such as antibiotics and
antiresistance compounds. It is important, however, that each round of culture be
long enough to allow the benefits of compound production to accrue, lest the
disruption of spatial structure in passages have a negative effect on selection for
public goods production. (See Westhoff et al. [27].) As the optimal values for the
diffusion resistance (for cells, nutrients, and compounds) and nutrient concentra-
tions of the medium, the densities of producer and target, and the degree of
resistance of the target cannot be precisely determined a priori, and evolution has
a stochastic component, it is advisable to run the evolution experiment in a
high-throughput manner with different levels of the above-mentioned parame-
ters, as well as a large number of replicates. The level of resistance can be varied
by genetic manipulation of the target organism or the addition of an antiresis-
tance compound (e.g., a -lactamase inhibitor), as relevant.
BOX 2―POTENTIAL PROBLEMS AND SUGGESTED SOLUTIONS
Here we, on theoretical grounds, discuss potential problems and suggest solutions
with special emphasis on the protocol skeleton in Box 1.
1. The selection pressure for overcoming the target’s resistance mechanism is
swamped by selection for adapting to the growth medium, etc. This is what the
preevolution (point 1) in the protocol in Box 1 is aimed to address.
2. The target organism evolves to survive transfers and then coevolves with the
producer. Depending on the extent of the problem, whether affected repli-
cates show interesting results, and practical considerations, affected samples
may be treated with, e.g., a cocktail of antibiotics to which the target—but not
the producer—is sensitive, left as they are, or discarded.
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3. The timing of antibiotic production is suboptimal for relieving competition. This
may itself evolve to the better. It can also be addressed when the producer
strain is chosen. For strains in which production is induced by nutrient
limitation (a common feature), nutrient competition with the target is ex-
pected to promote production.
4. The size of the producer population has conflicting effects. Increasing producer
population size increases the efficacy of selection (and decreases the effect of
drift). It also widens the range of variation available for selection to act upon,
since a larger number of cells provides more opportunity for relevant muta-
tions to occur. However, within a limited culture volume, increasing popula-
tion size increases population density. This weakens the link between the
benefit conferred by, e.g., an improved compound and the genotype that
gives rise to it, because at a higher population density, cells with other
genotypes are closer, and therefore more likely to share the benefit of the
improvement, despite not encoding it. This trade-off can be alleviated by the
use of larger culture volumes. On the other hand, smaller volumes are more
conducive to high-throughput methods.
5. The competition with the target bacterium, and thus the selection pressure on the
producer, is too strong or weak. The bacteria and medium should be chosen so as
to create antagonistic interaction, e.g., competition. This may be easier if the
producer and target are ecologically similar. Relevant resistance can be achieved
by genetic manipulation. As the killing efficiency increases during the evolutionary
process, competition grows weaker. The strength of competition can be adjusted
by using different target inoculum sizes for different sets of replicates or in different
phases of the process. The degree of resistance can also be varied (see Box 1).
6. Genetic variation is depleted. Strong selection and genetic bottlenecks in
culture transfers deplete genetic variation which, in turn, limits the scope for
further evolution. Therefore, selection should not be too strong, and bottle-
necks should not be too narrow. Given limited culture volume, the benefit of
wide bottlenecks may trade off against the need to provide enough room for
the population to expand under selection in each growth cycle. If necessary,
a mutagen or mutator strain can be used to ensure that adequate levels of
variation are maintained throughout the process.
7. The evolved compound kills the target but is unsuitable as a drug for other
reasons. It seems implausible that this problem could be circumvented alto-
gether. Some sources of problems may be possible to address by making the
experimental evolution environment as similar as practically possible to the in
vivo context in which the compound should be used. It is worth noting that
the Waksman platform should be subject to this problem, but nonetheless, it
was incredibly successful (2).
8. The chemical space that can be reached by evolution has already been explored
in drug discovery programs. Given the difference between natural products and
medicinal chemistry compounds (28) and, plausibly, between the fitness
landscapes for antimicrobial natural products evolving in nature and under
specific resistance-induced selection in the laboratory, this seems unlikely. In
addition, it is estimated that only a small fraction of natural product
antimicrobial compounds have been explored (14).
9. Evolution is too slow. The natural products in current use may have evolved over
millions of years, and useful evolution on reasonable time scales may not be
feasible. However, a similar argument applies to the evolution of antibiotic resis-
tance in nature, but in the health care setting, it has occurred over years, and in
experimental evolution in vitro over weeks (29). In addition, the evolution of
antibiotic production from a previously silent pathway has been achieved by
experimental evolution of an actinomycete for 4 months (7).
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10. The evolutionary response is not useful. In addition to the evolution of novelty
or modification, increased target killing can be achieved by a mere increase in
the production of the original compound. However, both theory and experi-
mental results indicate that the level of production should evolve to an
optimum (24), where it should remain constant until other changes occur. The
producer may also escape competition with the target by evolving to be less
dependent on a limiting nutrient competed over. This may be addressed by
inclusion of a sensitive target during the preevolution phase to saturate this
potential, if possible. In addition, the serial passage procedure may favor
mutants that have increased rates of growth (or sporulation, depending on the
exact protocol) for any reason. Consequently, a large number of replicates is
advisable to maximize the chances of useful evolutionary responses. Further
analyses (see Box 1) can separate different kinds of responses. It is also worth
noting that killing or inhibition of the competitor to increase nutrient avail-
ability is expected to be selected for even if other adaptations, such as
increased growth rate, evolve first.
11. Production of the original compound is turned off. If there is a cost of compound
production, and the target organism is so highly resistant to the original
antibiotic that production of it does not pay off for the producer, selection
disfavors production. This can lead to silencing of the pathway. If so, the
compound cannot be improved by selection (because genetic variation in the
pathway is not phenotypically manifest in a produced compound). The evo-
lution of any antiresistance compounds would also be compromised, as these
are efficacious only in conjunction with an antibiotic of the right type. This can
be mitigated by optimizing the degree of resistance (see Box 1). A similar issue
may occur during the preevolution phase, when selection for compound
production is lacking. This trades off against the benefits of preevolution. If the
goal is not to modify an existing compound, but to turn on a silent pathway,
this should not be a problem.
12. The structured medium limits oxygen availability. A medium designed to limit
the diffusion of cells and antibiotic compounds would also decrease the access
of oxygen from the air to cells far away from the medium’s surface, a potential
problem for strictly aerobic bacteria, such as streptomycetes. One approach
would be to make the medium porous. Another is to accept that growth is
confined to the volume close to the surface. The main drawback is that this
constrains the useful volume of medium, especially if the procedure is to be
run in a microwell format.
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